XPH vs. LFSC
Compare and contrast key facts about SPDR S&P Pharmaceuticals ETF (XPH) and F/m Emerald Life Sciences Innovation ETF (LFSC).
XPH and LFSC are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006. LFSC is an actively managed fund by F/m Investments. It was launched on Oct 30, 2024.
Performance
XPH vs. LFSC - Performance Comparison
Loading graphics...
XPH vs. LFSC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | -3.32% | 31.60% | -6.21% |
LFSC F/m Emerald Life Sciences Innovation ETF | -4.45% | 56.54% | -6.02% |
Returns By Period
In the year-to-date period, XPH achieves a -3.32% return, which is significantly higher than LFSC's -4.45% return.
XPH
- 1D
- 5.32%
- 1M
- -5.56%
- YTD
- -3.32%
- 6M
- 13.19%
- 1Y
- 24.45%
- 3Y*
- 11.04%
- 5Y*
- 2.79%
- 10Y*
- 3.82%
LFSC
- 1D
- 6.16%
- 1M
- -3.82%
- YTD
- -4.45%
- 6M
- 17.66%
- 1Y
- 55.83%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XPH vs. LFSC - Expense Ratio Comparison
XPH has a 0.35% expense ratio, which is lower than LFSC's 0.54% expense ratio.
Return for Risk
XPH vs. LFSC — Risk / Return Rank
XPH
LFSC
XPH vs. LFSC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and F/m Emerald Life Sciences Innovation ETF (LFSC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XPH | LFSC | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.00 | 1.93 | -0.92 |
Sortino ratioReturn per unit of downside risk | 1.47 | 2.65 | -1.18 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.33 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | 1.77 | 3.20 | -1.43 |
Martin ratioReturn relative to average drawdown | 5.52 | 8.96 | -3.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| XPH | LFSC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.00 | 1.93 | -0.92 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.17 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.94 | -0.57 |
Correlation
The correlation between XPH and LFSC is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
XPH vs. LFSC - Dividend Comparison
XPH's dividend yield for the trailing twelve months is around 0.69%, while LFSC has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XPH SPDR S&P Pharmaceuticals ETF | 0.69% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
LFSC F/m Emerald Life Sciences Innovation ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XPH vs. LFSC - Drawdown Comparison
The maximum XPH drawdown since its inception was -48.03%, which is greater than LFSC's maximum drawdown of -29.74%. Use the drawdown chart below to compare losses from any high point for XPH and LFSC.
Loading graphics...
Drawdown Indicators
| XPH | LFSC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -48.03% | -29.74% | -18.29% |
Max Drawdown (1Y)Largest decline over 1 year | -13.15% | -16.25% | +3.10% |
Max Drawdown (5Y)Largest decline over 5 years | -31.63% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -35.97% | — | — |
Current DrawdownCurrent decline from peak | -7.29% | -11.08% | +3.79% |
Average DrawdownAverage peak-to-trough decline | -17.37% | -8.25% | -9.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.23% | 5.80% | -0.57% |
Volatility
XPH vs. LFSC - Volatility Comparison
The current volatility for SPDR S&P Pharmaceuticals ETF (XPH) is 9.49%, while F/m Emerald Life Sciences Innovation ETF (LFSC) has a volatility of 10.35%. This indicates that XPH experiences smaller price fluctuations and is considered to be less risky than LFSC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| XPH | LFSC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.49% | 10.35% | -0.86% |
Volatility (6M)Calculated over the trailing 6-month period | 16.38% | 19.97% | -3.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.72% | 29.24% | -4.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.56% | 29.31% | -8.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.22% | 29.31% | -7.09% |